Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation. Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology. We are also researching a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to turn this scientific promise into commercially successful products, addressing important clinical needs.
Evgen Pharma is a publicly quoted company. It joined the AIM market of the London Stock Exchange in October 2015 and its shares trade under the ticker symbol EVG.Find out more
Our clinical pipeline is derived from our proprietary Sulforadex® platform technology; a means of synthesising and concurrently stabilising sulforaphane-based compounds in a solid dose form. Lead product, SFX-01, has produced positive results in an open-label Phase II trial in patients with ER+ metastatic breast cancer that had previously become resistant to all prior hormone therapies
The Sulforadex® stabilisation technology means that sulforaphane, and related analogues, can be delivered as a stable active in an oral pharmaceutical product.Find out more